Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms

Area of Science:

• Neuro-oncology
• Cancer Therapy
• Immunology

Background:

• Glioblastoma (GBM) is an aggressive primary brain tumor with poor patient prognosis.
• Current treatments for GBM are limited by the blood-brain barrier (BBB) and acquired drug resistance.
• Despite available multimodal therapies, patient outcomes remain suboptimal.

Purpose of the Study:

• To review current and emerging therapeutic strategies for glioma.
• To discuss innovative approaches targeting epigenetic factors, immunotherapy, gene therapy, and vaccines.
• To evaluate the potential of immunotherapy in overcoming BBB limitations for brain tumor treatment.

Main Methods:

• Literature review of clinical and preclinical investigations.
• Analysis of current glioma treatment options.
• Discussion of novel therapeutic tactics, including immunotherapy.

Main Results:

• Ineffective drug delivery across the BBB and drug resistance are major hurdles in glioma treatment.
• Emerging therapies such as epigenetic targeting and immunotherapy offer potential for improved efficacy.
• The identification of central nervous system lymphatics supports immunotherapy as a viable strategy to cross the BBB.

Conclusions:

• Glioblastoma treatment requires innovative approaches to overcome existing therapeutic challenges.
• Immunotherapy presents a promising avenue for enhancing anti-glioma treatment efficacy.
• Further research into novel strategies is crucial for improving glioblastoma patient prognoses.